PMC:7784786 / 0-280
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 3 | 8-11 | Gene | denotes | CD6 | Gene:923 |
| 4 | 51-59 | Species | denotes | patients | Tax:9606 |
| 5 | 42-50 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 33 | 231-241 | Chemical | denotes | Itolizumab | MESH:C000597346 |
| 36 | 127-135 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T1 | 65-90 | Phenotype | denotes | cytokine-release syndrome | http://purl.obolibrary.org/obo/HP_0033041 |
| T2 | 154-179 | Phenotype | denotes | cytokine-release syndrome | http://purl.obolibrary.org/obo/HP_0033041 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-113 | Sentence | denotes | An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases |
| T2 | 115-123 | Sentence | denotes | Abstract |
| T3 | 124-230 | Sentence | denotes | In COVID-19, the inflammatory cytokine-release syndrome is associated with the progression of the disease. |